Luteolin is effective in the non‐small cell lung cancer model withL858R/T790M EGFreceptor mutation and erlotinib resistance
British Journal of Pharmacology2014Vol. 171(11), pp. 2842–2853
Citations Over TimeTop 10% of 2014 papers
Zhuan Hong, Xiang Cao, Na Li, Yizhou Zhang, Lei Lan, Yi Zhou, Xiaolong Pan, Lei Shen, Zhimin Yin, Lan Luo
Abstract
Luteolin may be a potential candidate for NSCLC therapy, especially for treatment of patients with acquired erlotinib-resistant NSCLC.
Related Papers
- → Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus(2007)284 cited
- → Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors: Tissue Analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01(2005)249 cited
- → Three Cases of Long-Lasting Tumor Control with Erlotinib after Progression with Gefitinib in Advanced Non-Small Cell Lung Cancer(2007)35 cited
- Comparison of the therapeutic outcome between gefitinib and erlotinib in female patients with non-small-cell lung cancer(2009)
- Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatment(2011)